Drug intelligence / Profile preview

PBI-01220

Development stage: Preclinical
Lead developer: Phoenix Biotechnology
Modality: Small Molecules

Overview

PBI-01220 is a botanical drug candidate derived from *Nerium oleander* extract, developed by Phoenix Biotechnology for the treatment of viral diseases. The extract's primary active component is oleandrin, a cardiac glycoside that functions by binding to and inhibiting the Na,K-ATPase enzyme. This mechanism is believed to interfere with viral replication and host cell entry. Preclinical studies have indicated that PBI-01220 exhibits potent antiviral activity at concentrations significantly lower than those required for its potential anticancer effects. It is part of a broader pipeline of oleander-derived products targeting various conditions, including cancer and neurodegenerative disorders.

Other names: Nerium oleander extractNOE

Targets

HSPA5 (Heat shock protein family A member 5)

Beyond the preview

Go deeper on PBI-01220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBI-01220.

Explore the full profile